Consensus and Update on the Definition of On-Treatme Diphosphate Associated With Ischemia and Bleeding

Journal of the American College of Cardiology

62, 2261-2273

DOI: 10.1016/j.jacc.2013.07.101

Citation Report

#	Article	IF	Citations
1	Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vascular Health and Risk Management, 2014, 10, 177.	1.0	13
2	A Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention: The CAPITAL RELOAD Study. PLoS ONE, 2014, 9, e92078.	1.1	15
3	Thereâ€™s life in the old dog yet: Clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients. Thrombosis and Haemostasis, 2014, 112, 10-11.	1.8	2
4	Thrombin-induced platelet-fibrin clot strength: Relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thrombosis and Haemostasis, 2014, 111, 713-724.	1.8	22
5	Lower Loading Dose of Prasugrel Compared with Conventional Loading Doses of Clopidogrel and Prasugrel in Korean Patients Undergoing Elective Coronary Angiography: A Randomized Controlled Study Evaluating Pharmacodynamic Efficacy. Korean Circulation Journal, 2014, 44, 386.	0.7	8
6	Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 1198-1208.	1.8	6
7	Direct oral anticoagulants and antiplatelet agents. Hamostaseologie, 2014, 34, 78-84.	0.9	16
8	Pharmacodynamic Effects of Cilostazol Versus Clopidogrel in Stented Patients under Proton Pump Inhibitor Co-administration: The ACCEL-PARAZOL Study. Journal of Atherosclerosis and Thrombosis, 2014, 21, 1121-1139.	0.9	4
9	Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. Expert Opinion on Pharmacotherapy, 2014, 15, 2205-2217.	0.9	4
10	Mean platelet volume may not be related to clopidogrel resistance in patients with acute coronary syndrome. Anatolian Journal of Cardiology, 2014, 14, 405-407.	0.4	1
11	Platelet Function Tests: A Review of Progresses in Clinical Application. BioMed Research International, 2014, 2014, 1-7.	0.9	55
12	Should obese people be allowed to rise to high altitude?. Anatolian Journal of Cardiology, 2014, 14, 407-408.	0.4	0
13	Letter by Gurbel et al Regarding Article, â€œAdministration of a Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch From Ongoing Clopidogrel Treatment to Ticagrelor in Patients With Acute Coronary Syndromeâ€• Circulation: Cardiovascular Interventions, 2014, 7, 273-273.	1.4	1
14	On the interference of sildenafil on platelet aggregation: An ex vivo pilot study. IJC Metabolic & Endocrine, 2014, 4, 73-74.	0.5	0
15	Precision and Reliability of 5 Platelet Function Tests in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy. Clinical Chemistry, 2014, 60, 1524-1531.	1.5	76
16	Use of Antiplatelet Drugs After Cardiac Operations. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 223-230.	0.4	5
17	Impact of Gene Polymorphisms, PlateletÂReactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in PatientsÂWithÂNonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 1117-1127.	1.1	38
18	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Reviews Cardiology, 2014, 11, 597-606.	6.1	267

#	Article	IF	Citations
19	Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2014, 12, 463-474.	0.6	2
20	Switching Patients from Clopidogrel to Prasugrel in Acute Coronary Syndrome: Impact of the Clopidogrel Loading Dose on Platelet Reactivity. Journal of Interventional Cardiology, 2014, 27, 365-372.	0.5	10
21	Right here waiting...?. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 3099-3100.	0.4	0
22	Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open, 2014, 4, e005781.	0.8	21
23	Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. British Journal of Anaesthesia, 2014, 113, 970-976.	1.5	91
24	Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes. Cardiology in Review, 2014, 22, 313-318.	0.6	6
25	Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: Comparative effects of prasugrel and ticagrelor on platelet reactivity. International Journal of Cardiology, 2014, 174, 874-876.	0.8	15
26	Reply to Letter to the Editor: â€œAdenosine di-phosphate receptor antagonist discontinuation management prior to coronary artery surgeryâ€• International Journal of Cardiology, 2014, 172, 221-222.	0.8	0
27	Highlights of the Year in JACC 2013. Journal of the American College of Cardiology, 2014, 63, 570-602.	1.2	2
28	Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing. Journal of the American College of Cardiology, 2014, 63, 1061-1070.	1.2	81
29	Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 1500-1509.	1.2	85
30	The use of platelet function testing in PCI and CABG patients. Blood Reviews, 2014, 28, 109-121.	2.8	17
31	Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2014, 7, 113-124.	1.4	67
32	Pharmacodynamic Effects of Cangrelor onÂPlatelet P2Y12 Receptorâ€“Mediated Signaling in Prasugrel-Treated Patients. JACC: Cardiovascular Interventions, 2014, 7, 426-434.	1.1	28
33	Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. American Heart Journal, 2014, 167, 909-914.	1.2	48
34	Targeting platelet receptor function in thrombus formation: The risk of bleeding. Blood Reviews, 2014, 28, 9-21.	2.8	43
35	Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood, 2014, 124, 689-699.	0.6	28
36	Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study. American Heart Journal, 2014, 168, 674-681.e1.	1.2	21

#	Article	IF	Citations
37	Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. Thrombosis Research, 2014, 134, 939-944.	0.8	18
38	Relationship Between ABCB1 Polymorphisms, Thromboelastography and Risk of Bleeding Events in Clopidogrel-Treated Patients With ST-Elevation Myocardial Infarction. Thrombosis Research, 2014, 134, 970-975.	0.8	25
40	Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. American Heart Journal, 2014, 168, 530-536.	1.2	50
41	Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 64, 863-871.	1.2	88
42	Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations. Pharmacotherapy, 2014, 34, 973-990.	1.2	2
43	Correlation Between Point-of-Care Platelet Function Testing and Bleeding After Coronary Angiography According to Two Different Definitions for Bleeding. American Journal of Cardiology, 2014, 114, 1347-1353.	0.7	7
44	The Chronovariability of Platelet Reactivity. Journal of the American College of Cardiology, 2014, 64, 369-371.	1.2	0
45	Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet, The, 2014, 384, 1577-1585.	6.3	269
47	Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions. Annual Review of Genomics and Human Genetics, 2014, 15, 349-370.	2.5	128
48	Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity. Journal of Thrombosis and Thrombolysis, 2014, 38, 459-469.	1.0	18
49	Resistance to antiplatelet drugs: what progress has been made?. Expert Opinion on Pharmacotherapy, 2014, 15, 2553-2564.	0.9	30
50	Platelet Reactivity Is Preferred Over Genotyping in Monitoring Efficacy of Antiplatelet Therapy. JACC: Cardiovascular Interventions, 2014, 7, 448.	1.1	0
51	Tratamiento antiagregante plaquetario personalizado. Revista Espanola De Cardiologia, 2014, 67, 480-487.	0.6	10
52	How to manage prasugrel and ticagrelor in daily practice. European Journal of Internal Medicine, 2014, 25, 213-220.	1.0	11
53	Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study. International Journal of Cardiology, 2014, 174, 129-132.	0.8	5
54	Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy. Thrombosis Research, 2014, 134, 96-104.	0.8	5
55	Fixed combination dual antiplatelet therapy and the risk of stent thrombosis. International Journal of Cardiology, 2014, 174, e79-e80.	0.8	0
56	Personalized Antiplatelet Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 480-487.	0.4	1

#	Article	IF	Citations
57	Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 609-620.	1.5	3
58	â€œEast Asian Paradoxâ€• Challenge for the Current Antiplatelet Strategy of â€œOne-Guideline-Fits-All Racesâ€•in Acute Coronary Syndrome. Current Cardiology Reports, 2014, 16, 485.	1.3	136
59	Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. Expert Review of Neurotherapeutics, 2014, 14, 723-734.	1.4	0
60	Platelet Function Testing in Contemporary Clinical and Interventional Practice. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 300.	0.4	34
61	Efficacy and safety of prasugrel in acute coronary syndrome patients. Clinical Biochemistry, 2014, 47, 516-528.	0.8	7
62	A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 342-351.	1.8	41
63	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. Thrombosis and Haemostasis, 2014, 112, 311-322.	1.8	7
64	Ticagrelor vs prasugrel one-month maintenance therapy: Impact on platelet reactivity and bleeding events. Thrombosis and Haemostasis, 2014, 112, 551-557.	1.8	47
65	Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Thrombosis and Haemostasis, 2014, 112, 1190-1197.	1.8	27
66	New Insights for Low Dosing With the New P2Y₁₂ Inhibitors. Circulation Journal, 2014, 78, 2840-2842.	0.7	2
67	The Clopidogrel-Statin Interaction. Circulation Journal, 2014, 78, 592-594.	0.7	9
68	PRASFIT-ACS: Important Evidence Against a â€œOne-Guideline-Fits-All-Racesâ€•Approach to Antiplatelet Therapy. Circulation Journal, 2014, 78, 2563.	0.7	1
69	Does the VerifyNow P2Y12 assay overestimate â€œtherapeutic responseâ€•to clopidogrel?. Thrombosis and Haemostasis, 2014, 111, 1150-1159.	1.8	14
70	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. American Heart Journal, 2015, 170, 706-714.	1.2	5
71	Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. Circulation Journal, 2015, 79, 1248-1254.	0.7	20
72	Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood, 2015, 126, 1823-1830.	0.6	51
73	Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Japanese Patients With Stable Coronary Artery Disease. Circulation Journal, 2015, 79, 2439-2444.	0.7	22
74	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors â€“ is an algorithm the answer?. Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	43

#	Article	IF	Citations
75	Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects. Blood Coagulation and Fibrinolysis, 2015, 26, 874-881.	0.5	12
76	No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis. Thrombosis Research, 2015, 136, 947-954.	0.8	9
77	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors â€“ is an algorithm the answer?. Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	31
78	Platelet function testing in acute cardiac care â€“ is there a role for prediction or prevention of stent thrombosis and bleeding?. Thrombosis and Haemostasis, 2015, 113, 221-230.	1.8	33
79	Calciumâ€Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel. Cardiovascular Therapeutics, 2015, 33, 264-269.	1.1	13
80	Outcomes following implantation of the biolimus A9â€eluting Bio<scp>M</scp>atrix coronary stent: Primary analysis of the eâ€<scp>B</scp>io<scp>M</scp>atrix registry. Catheterization and Cardiovascular Interventions, 2015, 86, 1151-1160.	0.7	13
81	Platelet Function Testing Before CABG is Recommended in the Guidelines: But Do We Have Enough Evidence?. Journal of Interventional Cardiology, 2015, 28, 233-235.	0.5	8
82	Venous stasis and whole blood platelet aggregometry. Blood Coagulation and Fibrinolysis, 2015, 26, 665-668.	0.5	14
83	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. Diabetes and Metabolism Journal, 2015, 39, 95.	1.8	40
84	Personalized antiplatelet therapy with P2Y 12 receptor inhibitors: benefits and pitfalls. Postepy W Kardiologii Interwencyjnej, 2015, 4, 259-280.	0.1	23
85	Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 2015, 114, 702-707.	1.8	18
86	The effect of acenocoumarol on the antiplatelet effect of clopidogrel. Thrombosis and Haemostasis, 2015, 114, 708-716.	1.8	3
87	Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE). PLoS ONE, 2015, 10, e0121620.	1.1	36
88	Comparison of Aggregometry with Flow Cytometry for the Assessment of AgonistsÂ´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy. PLoS ONE, 2015, 10, e0129666.	1.1	44
89	The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy. BioMed Research International, 2015, 2015, 1-8.	0.9	47
90	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2) Tj ETQq1 1 0.784314 rgBT /Over	0.7	8
91	Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting. BMJ Case Reports, 2015, 2015, bcr2014205227.	0.2	5
92	Impact of platelet phenotype on myocardial infarction. Biomarkers, 2015, 20, 17-25.	0.9	6

#	Article	IF	Citations
93	Platelet function tests: a comparative review. Vascular Health and Risk Management, 2015, 11, 133.	1.0	356
94	Joint effects of CYP2C19*2 and smoking status on clopidogrel responsiveness in patients with acute coronary syndrome. International Journal of Cardiology, 2015, 180, 196-198.	0.8	8
95	Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 370-377.	1.0	13
96	The future of P2Y₁₂ receptor antagonists. Platelets, 2015, 26, 392-398.	1.1	12
97	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in PatientsÂUndergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2015, 8, 1978-1987.	1.1	31
98	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. Future Cardiology, 2015, 11, 547-564.	0.5	17
99	Accumetrics-based clopidogrel dosing in endovascular neurosurgery. Neurological Research, 2015, 37, 998-1005.	0.6	10
100	Temporal Changes of Platelet Reactivity After Coronary Stentingâ€"A Thing to Think About. American Journal of Cardiology, 2015, 116, 824.	0.7	0
101	A Bigger Look Into the â€œTherapeutic Windowâ€•of Platelet Reactivity to Adenosine Diphosphate. JACC: Cardiovascular Interventions, 2015, 8, 1988-1989.	1.1	0
102	Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2122-2133.	1.1	16
103	Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?. Expert Opinion on Pharmacotherapy, 2015, 16, 449-452.	0.9	8
104	New Approaches to Inhibiting Platelets and Coagulation. Annual Review of Pharmacology and Toxicology, 2015, 55, 373-397.	4.2	44
105	Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary interventionâ€“ a systematic review and meta-analysis. Thrombosis Research, 2015, 135, 449-458.	0.8	39
106	High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. European Journal of Pharmacology, 2015, 751, 24-27.	1.7	37
107	Prevalence and significance of <scp>CYP</scp>2<scp>C</scp>19*2 and <scp>CYP</scp>2<scp>C</scp>19*17 alleles in a <scp>N</scp>ew <scp>Z</scp>ealand acute coronary syndrome population. Internal Medicine Journal, 2015, 45, 537-545.	0.5	6
108	Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets, 2015, 26, 563-569.	1.1	22
109	Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	164
110	Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. International Journal of Cardiology, 2015, 184, 772-795.	0.8	15

#	Article	IF	Citations
111	State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus. Current Cardiovascular Risk Reports, 2015, 9, 4.	0.8	16
112	Clopidogrel Response Variability: Etiology and Clinical Relevance. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	1
113	Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy. Current Atherosclerosis Reports, 2015, 17, 501.	2.0	3
114	Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. Journal of Thrombosis and Thrombolysis, 2015, 40, 76-82.	1.0	27
115	High On-Treatment Platelet Reactivity Associated With Prasugrel. Journal of Pharmacy Technology, 2015, 31, 38-42.	0.5	1
116	Hemostatic and Thrombotic Issues in Cardiac Surgery. Seminars in Thrombosis and Hemostasis, 2015, 41, 084-090.	1.5	57
117	Point-of-Care Testing in Critically Ill Patients. Seminars in Thrombosis and Hemostasis, 2015, 41, 075-083.	1.5	6
118	Reply. Journal of the American College of Cardiology, 2015, 65, 2154.	1.2	24
119	Reply. JACC: Cardiovascular Interventions, 2015, 8, 1002.	1.1	0
120	Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by) Tj ETQq1 1 0.784314 rgBT /O Journal of Cardiology, 2015, 190, 370-375.	1.8	14
121	Creatine kinase inhibits ADP-induced platelet aggregation. Scientific Reports, 2014, 4, 6551.	1.6	11
122	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation: Cardiovascular Interventions, 2015, 8, e001712.	1.4	16
123	New oral anticoagulant and antiplatelet agents for neurosurgeons. British Journal of Neurosurgery, 2015, 29, 614-621.	0.4	4
124	A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. International Journal of Cardiology, 2015, 197, 318-325.	0.8	15
125	Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors. Expert Review of Clinical Pharmacology, 2015, 8, 411-421.	1.3	4
126	Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2015, 8, e002232.	1.4	18
127	A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI. Indian Heart Journal, 2015, 67, 114-121.	0.2	8
128	The pharmacogenetic control of antiplatelet response: candidate genes andCYP2C19. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1599-1617.	1.5	22

#	Article	IF	Citations
129	Platelet reactivity assessment with VerifyNowÂ®: Substitute or complement for light transmission aggregometry?. International Journal of Cardiology, 2015, 178, 221-222.	0.8	0
130	The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. Thrombosis Research, 2015, 136, 87-93.	0.8	27
131	The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clinical Science, 2015, 128, 121-130.	1.8	38
132	Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. Archives of Cardiovascular Diseases, 2015, 108, 502-510.	0.7	8
133	Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1075-1083.	1.1	5
134	Bleeding and stent thrombosis on P2Y₁₂-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	1.0	297
135	Novel Antiplatelet Agents in Cardiovascular Medicine. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 383.	0.4	3
136	Impact of tailored anti-P2Y12 therapies in acute coronary syndromes. Pharmacogenomics, 2015, 16, 493-499.	0.6	4
137	RÃ©ponse biologique et clinique aux AAP. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2015, 2015, 32-34.	0.0	0
138	CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. International Journal of Cardiology, 2015, 186, 282-285.	0.8	6
139	Thresholds for Perioperative Administration of Hemostatic Blood Components and Coagulation Factor Concentrates: An Unmet Medical Need. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 768-776.	0.6	18
140	Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy. Journal of Thrombosis and Thrombolysis, 2015, 40, 331-339.	1.0	4
141	Monitoring of Anticoagulant Therapy. , 2015, , 135-171.		0
142	CYP450 pharmacogenomics: a cardiology perspective. Personalized Medicine, 2015, 12, 59-62.	0.8	0
143	Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. Platelets, 2016, 27, 1-12.	1.1	5
144	Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials, 2015, 16, 198.	0.7	15
145	Genetically Determined Platelet Reactivity and Related Clinical Implications. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 257-264.	1.0	5
146	Prasugrel hydrochloride for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 585-596.	0.9	4

#	Article	IF	Citations
147	Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity. American Journal of Cardiology, 2015, 115, 716-723.	0.7	30
148	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet, The, 2015, 386, 281-291.	6.3	209
149	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet, The, 2015, 386, 292-302.	6.3	59
150	The Optimal Duration of DualÂAntiplateletÂTherapy After Drug-ElutingÂStent Implantation. Journal of the American College of Cardiology, 2015, 65, 1311-1313.	1.2	4
151	Current State and Novel Approaches of Antiplatelet Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1327-1338.	1.1	62
152	Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics, 2015, 16, 303-313.	0.6	32
153	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 373, 1271-1275.	13.9	62
154	Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events. Platelets, 2015, 26, 651-656.	1.1	8
155	Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. Cardiovascular Revascularization Medicine, 2015, 16, 450-454.	0.3	12
156	Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy?. Platelets, 2015, 26, 608-609.	1.1	1
157	Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. Atherosclerosis, 2015, 243, 389-394.	0.4	11
158	Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregationin vitro: Insights using short thromboelastography. Platelets, 2015, 26, 689-692.	1.1	10
159	Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy. Cardiovascular Drugs and Therapy, 2015, 29, 443-450.	1.3	6
160	Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Expert Opinion on Pharmacotherapy, 2015, 16, 1739-1747.	0.9	18
161	Incidence, Predictors, and Impact ofÂPost-Discharge Bleeding After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 1036-1045.	1.2	344
162	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. European Journal of Clinical Pharmacology, 2015, 71, 1315-1324.	0.8	31
163	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, 2015, 170, 683-694.e3.	1.2	26
164	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. Progress in Cardiovascular Diseases, 2015, 58, 267-277.	1.6	22

#	Article	IF	Citations
165	Current Phase II drugs under investigation for the treatment of limb ischemia. Expert Opinion on Investigational Drugs, 2015, 24, 1447-1458.	1.9	3
166	Drugâ€"drug interactions between clopidogrel and novel cardiovascular drugs. European Journal of Pharmacology, 2015, 765, 332-336.	1.7	10
167	Non-traumatic splenic rupture on dual antiplatelet therapy with aspirin and ticagrelor after stenting for acute coronary syndrome. Journal of Cardiology Cases, 2015, 12, 65-67.	0.2	7
168	Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. Platelets, 2015, 26, 467-473.	1.1	25
169	<u>COM</u>parison of<u>P</u>latelet reactivity following pr<u>A</u>sugrel and ticagrelor loading dose in<u>S</u>T-<u>S</u>egment elevation myocardial infarctI<u>ON</u>patients: The COMPASSION study. Platelets, 2015, 26, 570-572.	1.1	14
170	Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. Platelets, 2015, 26, 521-529.	1.1	13
172	Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2015, 39, 1-7.	1.0	25
173	Novel antiplatelet agents in acute coronary syndrome. Nature Reviews Cardiology, 2015, 12, 30-47.	6.1	299
175	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. Thrombosis and Haemostasis, 2016, 115, 382-391.	1.8	14
176	Platelet activation is less enhanced in the new balloon expandable Edwards Sapien 3 valve compared to its predecessor model (Edwards Sapien XT). Thrombosis and Haemostasis, 2016, 115, 109-116.	1.8	7
177	Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. Chinese Medical Journal, 2016, 129, 2269-2274.	0.9	12
178	Correlation Between the CYP2C19 Phenotype Status and the Results of Three Different Platelet Function Tests in Cardiovascular Disease Patients Receiving Antiplatelet Therapy: An Emphasis on Newly Introduced Platelet Function Analyzer-200 P2Y Test. Annals of Laboratory Medicine, 2016, 36, 42-48.	1.2	15
179	High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice. Rational Pharmacotherapy in Cardiology, 2016, 12, 385-390.	0.3	1
180	The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count. PLoS ONE, 2016, 11, e0149053.	1.1	7
181	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Thrombosis and Haemostasis, 2016, 115, 823-825.	1.8	32
182	Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Thrombosis and Haemostasis, 2016, 115, 979-992.	1.8	14
183	Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors. Thrombosis and Haemostasis, 2016, 116, 1060-1069.	1.8	8
184	Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. Thrombosis and Haemostasis, 2016, 115, 7-24.	1.8	25

#	Article	IF	Citations
185	Impact of reticulated platelets on antiplatelet response to thienopyridines is independent of platelet turnover. Thrombosis and Haemostasis, 2016, 116, 941-948.	1.8	21
186	Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite?. Thrombosis and Haemostasis, 2016, 116, 1140-1149.	1.8	10
187	In Vitro Effects of Pantoprazole on Platelet Aggregation in Blood Samples From Clopidogrel and Aspirin-treated Patients. Journal of Cardiovascular Pharmacology, 2016, 68, 191-195.	0.8	0
188	Comparison of Immature Platelet Count toÂEstablished Predictors of PlateletÂReactivity During ThienopyridineÂTherapy. Journal of the American College of Cardiology, 2016, 68, 286-293.	1.2	57
189	Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clinical Pharmacology and Therapeutics, 2016, 100, 295-304.	2.3	36
190	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. International Journal of Cardiology, 2016, 220, 496-500.	0.8	11
191	Physician response to implementation of genotypeâ€tailored antiplatelet therapy. Clinical Pharmacology and Therapeutics, 2016, 100, 67-74.	2.3	47
192	Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. Platelets, 2016, 27, 777-783.	1.1	5
193	State of the art: Oral antiplatelet therapy. JRSM Cardiovascular Disease, 2016, 5, 204800401665251.	0.4	6
195	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1703-1713.	0.7	18
196	Platelet Function Tests. Seminars in Thrombosis and Hemostasis, 2016, 42, 258-267.	1.5	57
197	One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. International Journal of Cardiology, 2016, 215, 209-213.	0.8	17
198	Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. International Journal of Cardiology, 2016, 216, 190-193.	0.8	6
199	Antiplatelet therapy â€“ a summary for the general physicians. Clinical Medicine, 2016, 16, 152-160.	0.8	36
200	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUSâ€“TIMI 54. Journal of the American College of Cardiology, 2016, 67, 2732-2740.	1.2	179
201	Validation of a P2Y₁₂-receptor specific whole blood platelet aggregation assay. Platelets, 2016, 27, 668-672.	1.1	6
202	Platelet-Mediated Thrombosis. Circulation Research, 2016, 118, 1380-1391.	2.0	56
203	Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2016, 42, 360-368.	1.0	10

#	Article	IF	Citations
204	Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets, 2016, 27, 373-377.	1.1	24
205	First report of the point-of-care TEG: A technical validation study of the TEG-6S system. Platelets, 2016, 27, 642-649.	1.1	133
206	Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). Canadian Journal of Cardiology, 2016, 32, 1246.e13-1246.e19.	0.8	4
207	Long-Term P2Y12-Receptor Antagonists inÂPost-Myocardial Infarction Patients. Journal of the American College of Cardiology, 2016, 68, 1223-1232.	1.2	9
208	Abciximab as a bridging strategy to overcome morphineâ€“prasugrel interaction in STEMI patients. British Journal of Clinical Pharmacology, 2016, 82, 1343-1350.	1.1	30
209	CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. Thrombosis Research, 2016, 147, 108-114.	0.8	10
211	Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions: The PRAISE study. International Journal of Cardiology, 2016, 222, 639-644.	0.8	4
212	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic Proceedings, 2016, 91, 1413-1447.	1.4	10
213	In dubious battle: bleeding versus ischemic events. Journal of Thrombosis and Thrombolysis, 2016, 42, 294-295.	1.0	0
214	â€œRealâ€Worldâ€•Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. Catheterization and Cardiovascular Interventions, 2016, 88, 535-544.	0.7	55
215	Effect of longâ€term adherence to clopidogrel on the VASPâ€PRI after elective coronary stent implantation: a randomized controlled study. British Journal of Clinical Pharmacology, 2016, 82, 1486-1497.	1.1	6
217	Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2016, 134, 780-792.	1.6	82
218	Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet, The, 2016, 388, 2015-2022.	6.3	303
219	Antiplatelet strategies in elderly people: still a long way to go. Lancet, The, 2016, 388, 1962-1964.	6.3	3
220	Platelet function testing in cardiac surgery. Transfusion Medicine, 2016, 26, 319-329.	0.5	10
221	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease. JAMA Cardiology, 2016, 1, 795.	3.0	68
222	Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Platelets, 2016, 27, 576-582.	1.1	28
223	Relationship of Platelet Reactivity With Bleeding Outcomes During Longâ€Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Nonâ€STâ€Segment Elevation Acute Coronary Syndromes. Journal of the American Heart Association, 2016, 5, .	1.6	4

#	Article	IF	Citations
224	Lower Platelet Reactivity Is Associated with Presentation of Unstable Coronary Artery Disease. International Journal of Angiology, 2016, 25, 210-218.	0.2	1
225	The Paradox of Smoking and Clopidogrel Effectã€€â€“ Dr Jekyll or Mr Hyde? â€“. Circulation Journal, 2016, 80, 1529-1531.	0.7	2
226	The Conundrum of Platelet P2Y₁₂ Inhibition in ST-Segment Elevation Myocardial Infarction. Circulation Journal, 2016, 80, 2429-2431.	0.7	3
227	Preoperative hemostatic testing and the risk of postoperative bleeding in coronary artery bypass surgery patients. Journal of Cardiac Surgery, 2016, 31, 565-571.	0.3	14
228	Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. Heart, 2016, 102, 882-892.	1.2	3
229	Periprocedural platelet inhibition with cangrelor in P2Y12-inhibitor naÃ¯ve patients with acute coronary syndromes â€" A matched-control pharmacodynamic comparison in real-world patients. International Journal of Cardiology, 2016, 223, 848-851.	0.8	13
230	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. Biomarkers in Medicine, 2016, 10, 903-918.	0.6	8
231	Updates on Acute Coronary Syndrome. JAMA Cardiology, 2016, 1, 718.	3.0	127
232	Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?. Annals of Thoracic Surgery, 2016, 102, 2010-2017.	0.7	35
233	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. Journal of Thrombosis and Thrombolysis, 2016, 42, 558-565.	1.0	3
234	Î²â€blockers are associated with decreased leucocyteâ€“platelet aggregate formation and lower residual platelet reactivity to adenosine diphosphate after angioplasty and stenting. European Journal of Clinical Investigation, 2016, 46, 1041-1047.	1.7	7
235	<scp>ACS</scp> Treatment Continues to Improve: But Price Matters. Catheterization and Cardiovascular Interventions, 2016, 88, 544-545.	0.7	2
236	Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. Thrombosis and Haemostasis, 2016, 115, 213-221.	1.8	9
237	Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. Thrombosis and Haemostasis, 2016, 116, 638-650.	1.8	78
238	Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. BMC Cardiovascular Disorders, 2016, 16, 252.	0.7	9
239	Parathyroid Hormone Levels and Highâ€Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. Cardiovascular Therapeutics, 2016, 34, 209-215.	1.1	9
240	Pharmacogenetics in Oral Antithrombotic Therapy. Clinics in Laboratory Medicine, 2016, 36, 461-472.	0.7	8
241	Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy. Platelets, 2016, 27, 812-820.	1.1	3

#	Article	IF	Citations
242	Thrombelastography (TEGÂ®). , 2016, , 247-266.		1
243	Platelet reactivity in patients undergoing transcatheter aortic valve implantation. Journal of Thrombosis and Thrombolysis, 2016, 42, 11-18.	1.0	18
244	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. Journal of Thrombosis and Thrombolysis, 2016, 42, 186-196.	1.0	3
245	Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. Resuscitation, 2016, 105, 16-21.	1.3	10
246	Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for a randomized controlled trial. Trials, 2016, 17, 75.	0.7	10
247	Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. Platelets, 2016, 27, 796-804.	1.1	11
248	Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity. Platelets, 2016, 27, 446-451.	1.1	4
249	Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vascular Pharmacology, 2016, 77, 48-53.	1.0	23
250	Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. Vascular Pharmacology, 2016, 79, 6-10.	1.0	27
251	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 475-486.	0.4	15
252	High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. European Journal of Internal Medicine, 2016, 30, 49-54.	1.0	17
253	Electric impedance platelet aggregometry in cardiac surgery patients: A comparative study of two technologies. Platelets, 2016, 27, 185-190.	1.1	15
254	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine, 2016, 374, 625-635.	13.9	117
255	Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. European Heart Journal, 2016, 37, 245-252.	1.0	217
256	Clopidogrel Response Variability. Journal of Pharmacy Practice, 2016, 29, 26-34.	0.5	24
257	Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor. JACC: Cardiovascular Interventions, 2016, 9, 1089-1098.	1.1	35
258	Crushed Prasugrel Tablets in Patients WithÂSTEMI Undergoing Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 67, 1994-2004.	1.2	104
259	Protease receptor antagonism to target blood platelet therapies. Clinical Pharmacology and Therapeutics, 2016, 99, 72-81.	2.3	10

#	Article	IF	Citations
260	P2Y₁₂ receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. British Journal of Clinical Pharmacology, 2016, 81, 621-633.	1.1	27
261	Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 228-230.	1.1	1
262	The Antiplatelet Effect of Clopidogrel Decreases With Patient Age. Angiology, 2016, 67, 902-908.	0.8	11
263	Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy. Cardiovascular Drugs and Therapy, 2016, 30, 143-150.	1.3	22
265	Platelet Function Testing in Patients on Antiplatelet Medications. Seminars in Thrombosis and Hemostasis, 2016, 42, 306-320.	1.5	35
266	Effects of Ticagrelor Versus Clopidogrel inÂTroponin-Negative Patients With Low-Risk ACS Undergoing AdÂHoc PCI. Journal of the American College of Cardiology, 2016, 67, 603-613.	1.2	41
267	A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. European Heart Journal, 2016, 37, 2722-2730.	1.0	52
268	In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets, 2016, 27, 308-316.	1.1	6
269	Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell, 2016, 165, 111-124.	13.5	1,358
270	Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. American Journal of Cardiology, 2016, 117, 656-663.	0.7	18
271	Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 249-255.	0.6	11
272	Platelet Inhibition With Ticagrelor 60ÂmgÂVersus 90 mg Twice Daily in theÂPEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 2016, 67, 1145-1154.	1.2	108
273	Personalized Antiplatelet Therapy. JACC: Cardiovascular Interventions, 2016, 9, 105-106.	1.1	1
274	Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 189-197.	1.1	89
275	Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2016, 41, 656-662.	1.0	7
276	General Aspects of Platelet Function Tests. , 2016, , 35-58.		0
277	Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 219-227.	1.1	23
278	Platelet reactivity in MitraClip patients. Vascular Pharmacology, 2016, 77, 54-59.	1.0	14

#	Article	IF	Citations
279	Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome. Platelets, 2016, 27, 159-167.	1.1	9
280	Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure. Platelets, 2016, 27, 317-321.	1.1	22
281	Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Vascular Pharmacology, 2016, 79, 11-15.	1.0	22
282	Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. Platelets, 2016, 27, 301-307.	1.1	7
283	Does â€œsmokerâ€™s paradoxâ€•exist in clopidogrel-treated Turkish patients with acute coronary syndrome. Platelets, 2016, 27, 240-244.	1.1	5
284	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. Trends in Cardiovascular Medicine, 2016, 26, 321-334.	2.3	3
285	Liver Function is Associated With Response to Clopidogrel Therapy in Patients Undergoing Angioplasty and Stenting. Angiology, 2016, 67, 835-839.	0.8	4
286	Acetylsalicylic acid desensitization in patients with coronary artery disease: A comprehensive overview of currently available protocols. Vascular Pharmacology, 2016, 80, 43-49.	1.0	7
287	Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. Journal of Thrombosis and Thrombolysis, 2016, 41, 663-670.	1.0	21
288	Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nature Reviews Cardiology, 2016, 13, 11-27.	6.1	154
289	Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. Clinical Pharmacokinetics, 2016, 55, 359-367.	1.6	51
290	Optimal Duration of Dual Antiplatelet Therapy After DES Implantation. Angiology, 2016, 67, 224-238.	0.8	26
291	How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?. Platelets, 2016, 27, 59-65.	1.1	16
292	Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. Platelets, 2016, 27, 75-79.	1.1	17
293	Traditional clinical risk factors predict clopidogrel hypo-responsiveness in unselected patients undergoing non-emergent percutaneous coronary intervention. Platelets, 2016, 27, 51-58.	1.1	2
294	A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics Journal, 2016, 16, 71-78.	0.9	35
295	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 753-770.	0.4	53
296	Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies. Cardiovascular Intervention and Therapeutics, 2017, 32, 93-105.	1.2	13

#	Article	IF	Citations
297	Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor. JACC: Cardiovascular Interventions, 2017, 10, 121-129.	1.1	30
298	Platelet Reactivity. Journal of the American College of Cardiology, 2017, 69, 114.	1.2	2
299	SeQuent Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the DÃ¼sseldorf DCB registry. International Journal of Cardiology, 2017, 231, 68-72.	0.8	13
300	Platelet reactivity inhuman immunodeficiency virusinfected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE₂ST-HIV study. European Heart Journal, 2017, 38, ehw583.	1.0	25
301	The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 29-36.	1.2	15
302	The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions. Journal of Thrombosis and Haemostasis, 2017, 15, 618-623.	1.9	15
303	HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm. European Heart Journal, 2017, 38, ehw630.	1.0	5
304	Comparison of Multiplate and VerifyNow platelet function tests in predicting clinical outcome in patients with acute coronary syndromes. Thrombosis Research, 2017, 152, 14-19.	0.8	21
305	Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nature Reviews Cardiology, 2017, 14, 361-379.	6.1	76
306	Conundrums of Platelet Function Testing. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	0
307	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. American Journal of Cardiology, 2017, 119, 1135-1140.	0.7	5
308	Pharmacology: Inhibitors of P2Y12. , 2017, , 1253-1267.		1
309	Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 949-956.	1.1	59
310	Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design. International Journal of Stroke, 2017, 12, 321-325.	2.9	17
311	Parameters of complete blood count do not predict on-treatment platelet reactivity in acute coronary syndrome patients. Thrombosis Research, 2017, 152, 38-40.	0.8	0
312	Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. Journal of International Medical Research, 2017, 45, 134-146.	0.4	19
313	Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. Platelets, 2017, 28, 786-793.	1.1	24
314	Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. Platelets, 2017, 28, 706-711.	1.1	5

#	Article	IF	Citations
315	Bleeding associated with the management of acute coronary syndromes. Heart, 2017, 103, 546-562.	1.2	5
316	Diabetes mellitus and carotid artery plaques exhibiting high-intensity signals on MR angiography are related to increased platelet reactivity after carotid artery stenting. Journal of NeuroInterventional Surgery, 2017, 9, 106-110.	2.0	6
317	Pharmacogenomics of Antiplatelet Drugs. , 2017, , 1325-1340.		0
318	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 221-234.	1.4	43
319	Bleeding and thrombosis associated with ventricular assist device therapy. Journal of Heart and Lung Transplantation, 2017, 36, 1164-1173.	0.3	83
320	Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 120, 201-206.	0.7	16
321	Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Vascular Pharmacology, 2017, 93-95, 42-47.	1.0	10
322	Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. Journal of Cardiovascular Translational Research, 2017, 10, 359-367.	1.1	15
323	Switching P2Y12 Receptor Inhibiting Therapies. Interventional Cardiology Clinics, 2017, 6, 67-89.	0.2	10
324	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. Interventional Cardiology Clinics, 2017, 6, 151-166.	0.2	4
325	Cangrelor. Interventional Cardiology Clinics, 2017, 6, 39-47.	0.2	5
326	Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. European Journal of Clinical Pharmacology, 2017, 73, 1085-1094.	0.8	6
327	Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention. Coronary Artery Disease, 2017, 28, 478-485.	0.3	3
328	Oral antiplatelet therapy: impact for transfusion medicine. Vox Sanguinis, 2017, 112, 511-517.	0.7	11
329	Postoperative bleeding in coronary artery bypass patients on double antiplatelet therapy: predictive value of preoperative aggregometryâ€. European Journal of Cardio-thoracic Surgery, 2017, 52, 901-908.	0.6	21
330	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponinâ€Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	1.6	30
331	Reply. Journal of the American College of Cardiology, 2017, 69, 113-114.	1.2	0
332	Left main crossover stenting in a patient with severe thrombocytopenia due to aplastic anemia. Cardiovascular Intervention and Therapeutics, 2017, 32, 409-415.	1.2	3

#	Article	IF	Citations
333	How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS). Seminars in Thrombosis and Hemostasis, 2017, 43, 439-446.	1.5	9
334	The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology, 2017, 238, 110-116.	0.8	8
335	Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 190-198.	0.6	10
336	Association of measured platelet reactivity with changes in P2Y 12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. American Heart Journal, 2017, 187, 19-28.	1.2	14
337	P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial. International Journal of Cardiology, 2017, 230, 204-208.	0.8	13
338	East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1152-1159.	1.4	8
339	Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel. Clinical Pharmacology and Therapeutics, 2017, 101, 791-802.	2.3	26
340	Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis, 2017, 15, 473-476.	1.9	43
341	Novel strategies for assessing platelet reactivity. Future Cardiology, 2017, 13, 33-47.	0.5	18
342	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€“Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
343	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2017, 44, 355-361.	1.0	9
344	Dual antiplatelet therapy guided by platelet function testing. Lancet, The, 2017, 390, 1718-1720.	6.3	39
345	Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Nonâ€“ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial. Canadian Journal of Cardiology, 2017, 33, 1675-1682.	0.8	6
346	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. International Journal of Cardiology, 2017, 246, 20-25.	0.8	15
347	Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. American Heart Journal, 2017, 192, 105-112.	1.2	35
348	Association ofCYP2C19*2polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents. Pharmacogenomics, 2017, 18, 1225-1239.	0.6	5
349	Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients. Blood Coagulation and Fibrinolysis, 2017, 28, 383-388.	0.5	1
350	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients TreatedÂWith Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 1607-1617.	1.1	29

#	Article	IF	Citations
351	Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	26
352	Update on antithrombotic therapy after percutaneous coronary revascularisation. Lancet, The, 2017, 390, 810-820.	6.3	25
354	A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Cardiology, 2017, 138, 201-206.	0.6	3
355	APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice. International Journal of Cardiology, 2017, 244, 13-16.	0.8	6
356	P2Y12 receptor inhibitor resistance and coronary artery disease. Current Opinion in Cardiology, 2017, 32, 617-626.	0.8	1
358	Practical Aspects of Monitoring of Antiplatelet Therapy. Seminars in Thrombosis and Hemostasis, 2017, 43, 014-023.	1.5	5
359	Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets. Thrombosis Research, 2017, 149, 88-94.	0.8	32
360	Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting. Cardiovascular Intervention and Therapeutics, 2017, 32, 341-350.	1.2	14
361	Cell-derived microvesicles in cardiovascular diseases and antiplatelet therapy monitoring â€" A lesson for future trials? Current evidence, recent progresses and perspectives of clinical application. International Journal of Cardiology, 2017, 226, 93-102.	0.8	20
362	P2Y‹sub›12‹/sub› Reaction Units Threshold for Implementing Modified Antiplatelet Preparation in Coil Embolization of Unruptured Aneurysms: A Prospective Validation Study. Radiology, 2017, 282, 542-551.	3.6	28
363	Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 11-17.	1.4	30
364	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. JACC: Cardiovascular Interventions, 2017, 10, 2560-2570.	1.1	36
365	An Unresolved Question. JACC: Cardiovascular Interventions, 2017, 10, 2557-2559.	1.1	0
366	Successful coronary stenting in a patient with factor V deficiency in the absence of fresh frozen plasma transfusion. Medicine (United States), 2017, 96, e9274.	0.4	2
367	Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. Thrombosis and Haemostasis, 2017, 117, 727-733.	1.8	27
368	Antithrombotic therapy for acute coronary syndrome: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1240-1248.	1.8	41
369	A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. Thrombosis and Haemostasis, 2017, 117, 303-310.	1.8	25
370	On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. Thrombosis and Haemostasis, 2017, 117, 1644-1650.	1.8	6

#	Article	IF	Citations
371	A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Thrombosis and Haemostasis, 2017, 117, 188-195.	1.8	36
372	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thrombosis and Haemostasis, 2017, 117, 940-947.	1.8	21
373	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, The, 2017, 390, 1747-1757.	6.3	443
374	Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial. Journal of Thoracic Disease, 2017, 9, E440-E443.	0.6	2
375	Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. Frontiers in Pharmacology, 2017, 8, 738.	1.6	2
376	Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications. International Journal of Molecular Sciences, 2017, 18, 1803.	1.8	83
377	Factors related to on-treatment platelet aggregation assessed by multiple electrode aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin. Postepy W Kardiologii Interwencyjnej, 2017, 3, 210-217.	0.1	0
378	Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thrombosis and Haemostasis, 2017, 117, 580-588.	1.8	14
379	Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity. PLoS ONE, 2017, 12, e0188493.	1.1	4
380	Relationship between thromboelastography and long-term ischemic events as gauged by the response to clopidogrel in patients undergoing elective percutaneous coronary intervention. BioScience Trends, 2017, 11, 209-213.	1.1	7
382	The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. Cardiovascular Drugs and Therapy, 2017, 31, 433-444.	1.3	4
383	Peripheral interventions and antiplatelet therapy: Role in current practice. World Journal of Cardiology, 2017, 9, 583.	0.5	22
384	Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction. Thrombosis and Haemostasis, 2017, 117, 99-104.	1.8	14
385	Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. Korean Journal of Anesthesiology, 2017, 70, 13.	0.9	17
386	MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE. Rational Pharmacotherapy in Cardiology, 2017, 13, 107-115.	0.3	3
387	Advances in Antiplatelet Agents. , 2017, , 556-599.		1
388	Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor. Thrombosis and Haemostasis, 2018, 118, 362-368.	1.8	11
389	Platelet Transcriptome Profiling in HIVÂandÂATP-Binding Cassette Subfamily CÂMember 4 (ABCC4) asÂaÂMediator ofÂPlatelet Activity. JACC Basic To Translational Science, 2018, 3, 9-22.	1.9	28

#	Article	IF	Citations
390	Platelet function testing: dead or alive. Journal of Thrombosis and Haemostasis, 2018, 16, 984-986.	1.9	23
391	Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome. Thrombosis and Haemostasis, 2018, 118, 415-426.	1.8	5
392	Thromboelastography (TEG) Point-of-Care Diagnostic for Hemostasis Management. Point of Care, 2018, 17, 15-22.	0.5	24
393	Low Levels of High-Density Lipoprotein Cholesterol Are Linked to Impaired Clopidogrel-Mediated Platelet Inhibition. Angiology, 2018, 69, 786-794.	0.8	6
394	Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. American Journal of Cardiology, 2018, 122, 6-11.	0.7	13
395	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. Expert Opinion on Pharmacotherapy, 2018, 19, 653-665.	0.9	15
396	Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. Thrombosis and Haemostasis, 2018, 118, 852-863.	1.8	0
397	Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgeryâ€"The BIANCA Observational Study. Thrombosis and Haemostasis, 2018, 118, 864-872.	1.8	17
398	Impact of Platelet Transfusion on Intracerebral Hemorrhage in Patients on Antiplatelet Therapyâ€"An Analysis Based on Intracerebral Hemorrhage Score. World Neurosurgery, 2018, 111, e895-e904.	0.7	25
399	Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases, 2018, 111, 210-223.	0.7	22
400	Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity. Circulation, 2018, 137, 2231-2245.	1.6	68
401	Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. Scientific Reports, 2018, 8, 1229.	1.6	26
402	Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents. Journal of Thrombosis and Thrombolysis, 2018, 45, 432-439.	1.0	1
403	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€"Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	1.2	24
404	Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial. International Journal of Cardiology, 2018, 255, 8-14.	0.8	1
405	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. Progress in Cardiovascular Diseases, 2018, 60, 478-490.	1.6	61
406	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. Journal of Translational Medicine, 2018, 16, 92.	1.8	41
407	Pharmacogenomic Testing to Select Antiplatelet Therapy. Journal of the American College of Cardiology, 2018, 71, 1878-1881.	1.2	6

#	Article	IF	Citations
408	Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors. Journal of Atherosclerosis and Thrombosis, 2018, 25, 674-689.	0.9	3
409	Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation. Circulation Journal, 2018, 82, 353-360.	0.7	5
410	Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan. Circulation Journal, 2018, 82, 747-756.	0.7	41
411	Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor. Platelets, 2018, 29, 257-264.	1.1	12
412	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. International Journal of Cardiology, 2018, 259, 20-25.	0.8	18
413	Platelet Signaling Pathways and New Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e28-e35.	1.1	41
414	Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease. Circulation, 2018, 137, 2450-2462.	1.6	46
415	Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors. American Journal of Therapeutics, 2018, 25, e202-e212.	0.5	12
416	Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 452-461.	0.7	1
417	Personalizing antiplatelet therapies: What have we learned from recent trials?. Platelets, 2018, 29, 131-139.	1.1	8
418	Sepsis favors high-on-clopidogrel platelet reactivity. Platelets, 2018, 29, 76-78.	1.1	8
419	Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Review of Clinical Pharmacology, 2018, 11, 151-164.	1.3	57
420	Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 152-157.	1.4	16
421	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. Expert Review of Hematology, 2018, 11, 5-12.	1.0	17
422	Switch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS). Cardiovascular Revascularization Medicine, 2018, 19, 319-323.	0.3	4
423	Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?. Platelets, 2018, 29, 228-237.	1.1	3
424	Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Platelets, 2018, 29, 589-595.	1.1	3
425	Effects of prasugrel on membrane potential and contractile activity of rat ventricular myocytes. Pharmacological Reports, 2018, 70, 156-160.	1.5	4

#	Article	IF	Citations
426	Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. European Journal of Clinical Investigation, 2018, 48, e12861.	1.7	16
427	Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. Cardiovascular Revascularization Medicine, 2018, 19, 516-520.	0.3	20
428	T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients. Journal of Cardiovascular Translational Research, 2018, 11, 36-41.	1.1	7
429	Management of antiplatelet therapy in patients undergoing neuroendovascular procedures. Journal of Neurosurgery, 2018, 129, 890-905.	0.9	74
430	Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome. Medicine (United States), 2018, 97, e13381.	0.4	2
431	A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity. Chinese Medical Journal, 2018, 131, 508-515.	0.9	10
432	Design of the randomized, placeboâ€controlled evolocumab for early reduction of LDLâ€cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clinical Cardiology, 2018, 41, 1513-1520.	0.7	20
433	Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy?. Circulation, 2018, 138, 2145-2159.	1.6	28
434	The potential of genotype-guided antiplatelet therapy: promises and challenges. Expert Review of Precision Medicine and Drug Development, 2018, 3, 371-377.	0.4	0
435	Monitoring platelet function: what have we learned from randomized clinical trials?. Cardiovascular Diagnosis and Therapy, 2018, 8, 621-629.	0.7	5
436	Uncontrolled Diabetes Mellitus Has No Major Influence on the Platelet Transcriptome. BioMed Research International, 2018, 2018, 1-9.	0.9	6
437	Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. BMC Cardiovascular Disorders, 2018, 18, 217.	0.7	33
438	Successful Use of Recombinant Activated Factor VII to Reverse Ticagrelor-Induced Bleeding Risk: A Case Report. TH Open, 2018, 02, e346-e349.	0.7	3
439	P2Y ₁₂ -ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes. Circulation, 2018, 138, 1582-1596.	1.6	53
440	Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention. Thrombosis Research, 2018, 171, 38-44.	0.8	1
441	Platelet Reactivity and Early Outcomes after Transfemoral Aortic Valve Implantation. Thrombosis and Haemostasis, 2018, 118, 1832-1838.	1.8	15
442	De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention. Korean Circulation Journal, 2018, 48, 863.	0.7	21
443	Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention. Circulation, 2018, 138, 1301-1303.	1.6	2

#	Article	IF	Citations
445	Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction. Thrombosis Research, 2018, 172, 14-20.	0.8	2
446	Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation. Expert Review of Cardiovascular Therapy, 2018, 16, 735-748.	0.6	8
447	Meta-Analysis of Bleeding Risk Prediction Scores in Patients After Percutaneous Coronary Intervention on Dual Antiplatelet Therapy. American Journal of Cardiology, 2018, 122, 1843-1852.	0.7	11
448	Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel. Atherosclerosis, 2018, 278, 23-28.	0.4	18
449	Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?. Cardiovascular Innovations and Applications, 2018, 3, .	0.1	0
450	Risks of Opioids in ST-Elevation Myocardial Infarction: A Review. Drug Safety, 2018, 41, 1303-1308.	1.4	4
451	Inhibitory mechanisms of very lowâ€“dose rivaroxaban in nonâ€“ST-elevation myocardial infarction. Blood Advances, 2018, 2, 715-730.	2.5	38
452	Novel aspects of antiplatelet therapy in cardiovascular disease. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 439-449.	1.0	41
453	Efficacy of 2.5-mg Prasugrel in Elderly or Low-Body-Weight Patients. Circulation Journal, 2018, 82, 2326-2331.	0.7	12
454	Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. European Heart Journal, 2018, 39, 2749-2758.	1.0	40
455	The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy, 2018, 33, 109-118.	0.3	7
456	Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine Nâ€oxideâ€generating pathway, modulates platelet responsiveness and thrombosis risk. Journal of Thrombosis and Haemostasis, 2018, 16, 1857-1872.	1.9	104
457	Effect of thrombelastography on timing of coronary artery bypass grafting. Experimental and Therapeutic Medicine, 2018, 16, 579-584.	0.8	7
458	CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. Gene, 2018, 678, 226-232.	1.0	19
459	Thromboelastographyâ€‘derived parameters for the prediction of acute thromboembolism following nonâ€‘steroidal antiâ€‘inflammatory drugâ€‘induced gastrointestinal bleeding: A retrospective study. Experimental and Therapeutic Medicine, 2018, 16, 2257-2266.	0.8	3
460	Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy. Thrombosis and Haemostasis, 2018, 118, 1656-1667.	1.8	26
461	Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opinion on Pharmacotherapy, 2018, 19, 1389-1398.	0.9	5
462	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2018, 118, 1131-1140.	1.8	11

#	Article	IF	Citations
463	Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy. International Journal of Sports Medicine, 2018, 39, 646-652.	0.8	6
464	Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count. Translational Research, 2018, 200, 35-42.	2.2	9
465	Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed. Clinical Toxicology, 2018, 56, 1200-1203.	0.8	9
466	Platelet Reactivity and Risk of IschemicÂStroke After Coronary Drug-Eluting StentÂImplantation. JACC: Cardiovascular Interventions, 2018, 11, 1277-1286.	1.1	14
467	Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. , 2019, 193, 83-90.		16
468	Comparison of factors affecting platelet reactivity in various platelet function tests. Platelets, 2019, 30, 631-636.	1.1	18
469	Two common mutations within CYP2C19 affected platelet aggregation in Chinese patients undergoing PCI: a one-year follow-up study. Pharmacogenomics Journal, 2019, 19, 157-163.	0.9	7
470	High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. Journal of Cardiology, 2019, 73, 51-57.	0.8	11
471	Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series. Annals of Pharmacotherapy, 2019, 53, 171-177.	0.9	19
472	Pharmacodynamic-Guided Cangrelor Bridge Therapy for Orthotopic Heart Transplant. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 1054-1058.	0.6	4
473	Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator. Advances in Therapy, 2019, 36, 2296-2309.	1.3	4
474	The effect of the CYP2C19*2 allele on cardiovascular outcomes in patients with coronary artery stenting: a prospective study. Archives of Medical Science, 2019, 15, 837-844.	0.4	4
475	Proteaseâ€activated receptorâ€mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 383-390.	1.0	18
476	TRimetazidine as an Agent to affeCt clopidogrEl Response: The TRACER Study. Cardiology and Therapy, 2019, 8, 229-237.	1.1	3
477	Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCIâ€”Design and Rationale of the Randomized ISAR-PLASTER Trial. Thrombosis and Haemostasis, 2019, 119, 1539-1545.	1.8	26
478	Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Journal of Thrombosis and Haemostasis, 2019, 17, 2188-2195.	1.9	5
479	Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. Journal of Clinical Lipidology, 2019, 13, 788-796.	0.6	7
480	Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clinical Pharmacokinetics, 2019, 58, 1517-1532.	1.6	6

#	Article	IF	Citations
481	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	1.1	366
482	Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy. Thrombosis and Haemostasis, 2019, 119, 1527-1538.	1.8	7
483	Estimating short- and long-term reference change values and index of individuality for tests of platelet function. Clinical Biochemistry, 2019, 74, 54-59.	0.8	2
484	Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2019, 12, e007749.	1.4	2
485	Gut Microbial Metabolite Trimethylamine N-Oxide Is Related to Thrombus Formation in Atrial Fibrillation Patients. American Journal of the Medical Sciences, 2019, 358, 422-428.	0.4	29
486	Utility of Dual Antiplatelet Therapy for the Prevention of Subclinical Leaflet Thrombosis. JACC: Cardiovascular Interventions, 2019, 12, 19-21.	1.1	4
487	Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2019, 139, 1661-1670.	1.6	106
488	Interactions between clopidogrel and traditional Chinese medicine. Journal of Thrombosis and Thrombolysis, 2019, 48, 491-499.	1.0	28
489	Microvesicles from patients with acute coronary syndrome enhance platelet aggregation. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 507-512.	0.6	1
490	Radionuclide imaging of jeopardized myocardium: From the beginning of the race to the finish line. Journal of Nuclear Cardiology, 2021, 28, 1435-1437.	1.4	0
491	Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study. Thrombosis and Haemostasis, 2019, 119, 660-667.	1.8	12
492	Cardiovascular Risk Reduction. Critical Care Nursing Clinics of North America, 2019, 31, 15-30.	0.4	2
493	High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. Thrombosis Research, 2019, 175, 95-101.	0.8	14
494	Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCIâ€"the POPular Risk Score study. European Journal of Clinical Pharmacology, 2019, 75, 1201-1210.	0.8	16
495	Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2019, 321, 2428.	3.8	424
496	Pharmacokinetics and bioequivalence of low-dose clopidogrel in healthy Chinese volunteers under fasted and fed conditions. Drug Metabolism and Pharmacokinetics, 2019, 34, 300-307.	1.1	5
497	Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Vascular Pharmacology, 2019, 120, 106564.	1.0	12
498	The prognostic value of multiple electrode aggregometry and light transmittance aggregometry in stable cardiovascular patients with type 2 diabetes mellitus. Thrombosis Research, 2019, 180, 47-54.	0.8	4

#	Article	IF	Citations
499	Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial. BMJ Open, 2019, 9, e028595.	0.8	3
501	Platelet Function Monitoring. , 2019, , 79-88.		0
502	Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Journal of Thrombosis and Thrombolysis, 2019, 48, 413-421.	1.0	7
503	Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study). European Journal of Clinical Pharmacology, 2019, 75, 1059-1068.	0.8	11
504	Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. Thrombosis Research, 2019, 179, 87-94.	0.8	8
505	Clopidogrel Pharmacogenetics. Circulation: Cardiovascular Interventions, 2019, 12, e007811.	1.4	139
506	Impact of Antithrombotic Regimen and Platelet Inhibition Extent on Leaflet Thrombosis Detected by Cardiac MDCT after Transcatheter Aortic Valve Replacement. Journal of Clinical Medicine, 2019, 8, 506.	1.0	16
507	Optimal Antithrombotic Therapy for Patients with STEMI Undergoing PCI at High Risk of Bleeding. Current Atherosclerosis Reports, 2019, 21, 22.	2.0	3
508	Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. European Heart Journal, 2019, 40, 1942-1951.	1.0	41
509	Platelet reactivity patterns in patients treated with dual antiplatelet therapy. European Journal of Clinical Investigation, 2019, 49, e13102.	1.7	24
510	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. New England Journal of Medicine, 2019, 380, 1825-1833.	13.9	96
511	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2019, , 1-23.		0
512	Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting. Biomedicine and Pharmacotherapy, 2019, 113, 108773.	2.5	3
513	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
514	Platelet Function Testing in Clinical Research Trials. , 2019, , 683-700.		0
515	Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. Scientific Reports, 2019, 9, 3924.	1.6	16
516	Prevalence of clOpidogrel â€˜resIstaNceâ€™ in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study. Open Heart, 2019, 6, e000841.	0.9	11
517	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0

#	Article	IF	Citations
518	De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Chinese Medical Journal, 2019, 132, 197-210.	0.9	11
519	Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. Clinical Pharmacokinetics, 2019, 58, 1295-1307.	1.6	10
520	AÂrandomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIMEÂ3) trial. Netherlands Heart Journal, 2019, 27, 185-190.	0.3	8
521	Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients. Cardiovascular Drugs and Therapy, 2019, 33, 129-137.	1.3	17
522	Update in theÂManagement of Non-traumatic Thoracoabdominal Vascular Emergencies. , 2019, , 543-558.		0
523	Measuring high on-treatment platelet reactivity in clinical practice; should we use a panel of platelet function tests?. Blood Coagulation and Fibrinolysis, 2019, 30, 263-269.	0.5	3
524	Gender-based differences in platelet function and platelet reactivity to P2Y12Âinhibitors. PLoS ONE, 2019, 14, e0225771.	1.1	39
525	Platelet Reactivity in Patients on Aspirin and Clopidogrel Therapy Measured by a New Bedside Whole-Blood Assay. Journal of Cardiovascular Pharmacology, 2019, 73, 40-47.	0.8	14
526	Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Frontiers in Cardiovascular Medicine, 2019, 6, 176.	1.1	17
527	Safety of Percutaneous Dilatational Tracheotomy in Patients on Dual Antiplatelet Therapy and Anticoagulation. , 2019, 1, e0050.		9
528	Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease. Chinese Medical Journal, 2019, 132, 2292-2299.	0.9	1
529	Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention. Medicine (United States), 2019, 98, e14833.	0.4	17
530	Bioresorbable Vascular Scaffoldsâ€"Dead End or Still a Rough Diamond?. Journal of Clinical Medicine, 2019, 8, 2167.	1.0	18
531	Pharmacodynamic safety of clopidogrel monotherapy in patients under oral anticoagulation with a vitamin K antagonist undergoing coronary stent implantation. Platelets, 2019, 30, 714-719.	1.1	2
532	Exploration and validation of diphosphateâ€based <scp>Plasmodium LytB</scp> inhibitors using computational approaches. Journal of Molecular Recognition, 2019, 32, e2762.	1.1	5
533	Biomarkers for Antiplatelet Therapy. , 2019, , 139-148.		0
534	Anti-platelet and anti-coagulant therapy in peripheral arterial disease prior to surgical intervention. Vascular, 2019, 27, 299-311.	0.4	9
535	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Science Bulletin, 2019, 64, 166-179.	4.3	34

#	Article	IF	Citations
536	Serum gut microbe-dependent trimethylamine N-oxide improves the prediction of future cardiovascular disease in a community-based general population. Atherosclerosis, 2019, 280, 126-131.	0.4	34
537	DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. American Journal of Cardiovascular Drugs, 2019, 19, 75-86.	1.0	10
539	Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment. Platelets, 2019, 30, 915-922.	1.1	3
540	Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics. Thrombosis Research, 2019, 173, 27-34.	0.8	4
541	Impact of On-Clopidogrel Platelet Reactivity on Incidence of Hypoattenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 12-18.	1.1	32
542	Impact of platelet reactivity on long-term prognosis in Korean patients receiving percutaneous coronary intervention. Platelets, 2019, 30, 1030-1035.	1.1	4
543	Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases, 2019, 112, 199-216.	0.7	20
544	Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 22-32.	1.1	48
545	Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. Thrombosis and Haemostasis, 2019, 119, 264-273.	1.8	2
546	Comparison of In-Hospital Bleeding and Cardiovascular Events with High-Dose Bolus Tirofiban and Shortened Infusion to Short-Duration Eptifibatide as Adjunctive Therapy for Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 44-49.	0.7	2
547	Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR). Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 289-302.	0.6	25
548	Antiplatelet effects of aspirin and clopidogrel after left atrial appendage (LAA) occluder implantation. International Journal of Cardiology, 2019, 275, 95-100.	0.8	5
549	Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
550	Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation. Journal of Cardiology, 2019, 73, 198-203.	0.8	11
551	Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease. Platelets, 2019, 30, 752-761.	1.1	11
552	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. Platelets, 2019, 30, 105-111.	1.1	3
553	Circulating progenitor cells and their interaction with platelets in patients with an acute coronary syndrome. Platelets, 2019, 30, 314-321.	1.1	5
554	Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). British Journal of Pharmacology, 2019, 176, 988-999.	2.7	49

#	Article	IF	Citations
555	Monitoring of Antiplatelet Therapy in Children on Ventricular Assist Device Support: Comparison of Multiplate and Thromboelastography Platelet Mapping. ASAIO Journal, 2019, 65, 84-93.	0.9	13
556	Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis. Platelets, 2019, 30, 341-347.	1.1	8
557	Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 520-526.	0.4	14
558	Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation. Journal of Atherosclerosis and Thrombosis, 2020, 27, 13-24.	0.9	13
559	Aggregometry Response to Half-dose Prasugrel inÂFlow-diverting Stent Implantation. Clinical Neuroradiology, 2020, 30, 463-469.	1.0	10
560	Impact of lowâ€dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drugâ€eluting stent implantation: A randomized comparative study. Catheterization and Cardiovascular Interventions, 2020, 95, E8-E16.	0.7	3
561	Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial. Platelets, 2020, 31, 329-336.	1.1	5
562	Therapeutic Window of Clopidogrel and Ticagrelor in Patients With Critical Limb-Threatening Ischemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 158-163.	1.0	2
563	Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation. Heart and Vessels, 2020, 35, 312-322.	0.5	8
564	Management of bleeding and procedures in patients on antiplatelet therapy. Blood Reviews, 2020, 39, 100619.	2.8	14
565	Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition. Journal of Thrombosis and Thrombolysis, 2020, 50, 135-143.	1.0	19
566	Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI. Hellenic Journal of Cardiology, 2020, 61, 306-310.	0.4	6
567	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with monoâ€and dualâ€antiplatelet therapy. Journal of Thrombosis and Haemostasis, 2020, 18, 23-35.	1.9	13
568	Platelet aggregation is not altered among men with diabetes mellitus. Acta Diabetologica, 2020, 57, 389-399.	1.2	8
569	Increased platelet inhibition after switching from prasugrel to low-dose ticagrelor in Japanese patients with prior myocardial infarction. Journal of Cardiology, 2020, 75, 473-477.	0.8	7
570	What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 121-130.	1.0	6
571	Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets, 2020, 31, 945-951.	1.1	5
572	Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption. Journal of Cardiovascular Pharmacology, 2020, 75, 174-179.	0.8	3

#	Article	IF	Citations
573	Platelet-derived miRNAs as determinants of the antiplatelet response in clopidogrel-treated patients with ACS. Thrombosis Research, 2020, 186, 71-74.	0.8	14
574	Assessment of platelet function after discontinuation of ticagrelor. Acta Anaesthesiologica Scandinavica, 2020, 64, 526-531.	0.7	3
575	Advances in the Pharmacogenomics of Antiplatelet Therapy. American Journal of Therapeutics, 2020, 27, e477-e484.	0.5	6
576	Low Response to Clopidogrel in Coronary Artery Disease. American Journal of Therapeutics, 2020, 27, e133-e141.	0.5	9
577	Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis. BMC Cardiovascular Disorders, 2020, 20, 430.	0.7	5
578	Effect of CYP3A4*22 and PPAR-Î± Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes, 2020, 11, 1068.	1.0	2
579	High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study. Cardiovascular Diabetology, 2020, 19, 171.	2.7	14
581	Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes. Thrombosis and Haemostasis, 2020, 120, 1221-1229.	1.8	8
582	Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor. Vascular Pharmacology, 2020, 132, 106765.	1.0	16
583	Effects of Time-Interval since Blood Draw and of Anticoagulation on Platelet Testing (Count, Indices) Tj ETQq1 1 0.784314 rgBT /Over Clinical Medicine, 2020, 9, 2515.	1.0	17
584	Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. American Heart Journal, 2020, 228, 1-7.	1.2	7
585	The Effect of Low-Dose Ticagrelor on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad: The TWIST Pilot Study. Cardiology and Therapy, 2020, 9, 493-503.	1.1	1
586	On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Thrombosis and Haemostasis, 2021, 121, 923-930.	1.8	3
587	Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention. Perfusion (United Kingdom), 2020, , 026765912097858.	0.5	5
588	High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: Systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104877.	0.7	24
589	Predicting ischaemic events using platelet reactivity in patients receiving clopidogrel: Indirect metaâ€comparison among VerifyNow, light transmission aggregometry and thromboelastography. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 309-319.	1.2	0
590	Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		3
591	microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring. International Journal of Molecular Sciences, 2020, 21, 3477.	1.8	34

#	Article	IF	Citations
592	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077.	2.3	32
593	Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial. Journal of Clinical Medicine, 2020, 9, 1678.	1.0	1
594	Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS. Platelets, 2021, 32, 498-506.	1.1	3
595	Performance comparison of platelet function analyzers in cardiology patients: VerifyNow and Anysis-200 aspirin assays. Clinical Hemorheology and Microcirculation, 2020, 76, 33-42.	0.9	6
596	Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Thrombosis Research, 2020, 193, 130-138.	0.8	5
597	A novel mechanism of ACE inhibitionâ€“associated enhanced platelet reactivity: disproof of the ARB-MI paradox?. European Journal of Clinical Pharmacology, 2020, 76, 1245-1251.	0.8	2
598	Safety and efficacy of a pre-treatment antiplatelet regimen of unruptured intracranial aneurysms: a single-center experience. Neuroradiology, 2020, 62, 1029-1041.	1.1	9
599	Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With STâ€Segmentâ€“Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Longâ€Term Followâ€Up of the REDUCEâ€MVI Trial. Journal of the American Heart Association, 2020, 9, e014411.	1.6	15
600	Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Reactivity in Patients With Minor Stroke or TIA. Frontiers in Neurology, 2020, 11, 534.	1.1	6
601	Perioperative Bridging/Cessation of Antiplatelet Agents: 2020 Update. Current Anesthesiology Reports, 2020, 10, 273-281.	0.9	0
602	Current Antithrombotic Therapy: Beyond Coronary Artery Disease. Current Pharmaceutical Design, 2020, 26, 2683-2685.	0.9	1
603	Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machineâ€learning decision tree approaches. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1076-1086.	0.7	9
604	Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction. Platelets, 2020, 31, 1090-1093.	1.1	1
605	Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy. Cardiovascular Revascularization Medicine, 2020, 21, 1144-1149.	0.3	5
606	Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy, 2020, 34, 53-63.	1.3	20
607	High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction. Journal of Clinical Medicine, 2020, 9, 583.	1.0	4
608	Impact of smoking on platelet function of ticagrelor versus clopidogrel in minor stroke or transient ischaemic attack. European Journal of Neurology, 2020, 27, 833-840.	1.7	4
609	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. Thrombosis and Haemostasis, 2020, 120, 449-456.	1.8	10

#	Article	IF	Citations
610	Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. Journal of Clinical Medicine, 2020, 9, 194.	1.0	12
611	Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial). International Journal of Cardiology, 2020, 305, 11-17.	0.8	4
612	Assessing platelet reactivity after drug eluting stent implantation: state of the art. Expert Review of Cardiovascular Therapy, 2020, 18, 17-24.	0.6	1
613	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. Scientific Reports, 2020, 10, 6169.	1.6	14
614	Increased platelet reactivity after heart transplantation. Transplantation Reports, 2020, 5, 100044.	0.3	1
615	The Influence of Prostaglandin E1 and Use of Inhibitor Percentage on the Correlation between the Multiplate and VerifyNow in Patients on Dual Antiplatelet Therapy. Platelets, 2020, 32, 1-6.	1.1	7
616	The Role of Clopidogrel in 2020: A Reappraisal. Cardiovascular Therapeutics, 2020, 2020, 1-12.	1.1	55
617	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. Global Heart, 2020, 9, 457.	0.9	34
618	Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs, 2021, 21, 63-71.	1.0	7
619	Cangrelor dose titration using platelet function testing during cerebrovascular stent placement. Interventional Neuroradiology, 2021, 27, 88-98.	0.7	19
620	Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR). Platelets, 2021, 32, 120-129.	1.1	7
621	Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 43-49.	0.6	5
622	Genotypeâ€guided antiplatelet treatment versus conventional therapy: A systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 2199-2215.	1.1	6
623	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. Nature Reviews Cardiology, 2021, 18, 37-57.	6.1	42
624	The opioid-P2Y12 inhibitor interaction: Potential strategies to mitigate the interaction and consideration of alternative analgesic agents in myocardial infarction. , 2021, 217, 107665.		12
625	Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. Journal of Thrombosis and Thrombolysis, 2021, 51, 249-259.	1.0	6
626	The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study. Cardiology and Therapy, 2021, 10, 189-199.	1.1	8
627	Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 260-268.	1.0	4

#	Article	IF	Citations
628	The need of a multicomponent guiding approach to personalize clopidogrel treatment. Pharmacogenomics Journal, 2021, 21, 116-127.	0.9	8
629	Use of pCONUS HPC for the treatment of unruptured wide-necked bifurcation aneurysms: early clinical experience using single antiplatelet therapy. Stroke and Vascular Neurology, 2021, 6, 57-64.	1.5	3
630	Residual platelet reactivity after pre-treatment with ticagrelor prior to primary percutaneous coronary intervention is associated with suboptimal myocardial reperfusion. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 184-189.	0.4	1
631	Is a personalized pharmacotherapeutic approach closed for acute coronary syndrome?. Expert Opinion on Pharmacotherapy, 2021, 22, 527-529.	0.9	0
632	Platelet Reactivity Was Not Associated with Infarct Size after Primary Percutaneous Coronary Intervention. Chonnam Medical Journal, 2021, 57, 204.	0.5	0
633	Whole Blood Assay: ThromboelastometryÂâ€“ Basics. , 2021, , 45-66.		2
634	Low hemoglobin predicts highâ€platelet reactivity and major cardiovascular ischemic events at longâ€term followâ€up among <scp>ACS</scp> patients receiving dual antiplatelet therapy with ticagrelor. Catheterization and Cardiovascular Interventions, 2021, 98, 1309-1316.	0.7	6
635	The Total Thrombus Formation (T-TAS) platelet (PL) assay, a novel test that evaluates whole blood platelet thrombus formation under physiological conditions. Platelets, 2022, 33, 273-277.	1.1	4
636	Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Pharmacology Research and Perspectives, 2021, 9, e00738.	1.1	6
637	Clinical Use of Cangrelor After Percutaneous Coronary Intervention in Patients Requiring Mechanical Circulatory Support. Annals of Pharmacotherapy, 2021, 55, 1215-1222.	0.9	7
638	Clinical significance of high on-treatment platelet reactivity in patients with prolonged clopidogrel therapy. Korean Journal of Internal Medicine, 2021, 36, S80-S89.	0.7	0
639	Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men. Expert Review of Cardiovascular Therapy, 2021, 19, 301-312.	0.6	9
640	Comparison of VerifyNow, thromboelastography, and PL-12 in patients with minor ischemic stroke or transient ischemic attack. Aging, 2021, 13, 8396-8407.	1.4	8
641	Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy. Journal of Clinical Medicine, 2021, 10, 1565.	1.0	3
642	De-escalation of Prasugrel Results in Higher Percentage of Patients within Optimal Range of Platelet Reactivity: Analysis from the HOST-REDUCE-POLYTECH-ACS Trial. Thrombosis and Haemostasis, 2022, 122, 160-162.	1.8	4
643	Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock		
644	Linking Neutrophil Extracellular Traps and Platelet Activation: A Composite Biomarker Score for Predicting Outcomes after Acute Myocardial Infarction. Thrombosis and Haemostasis, 2021, 121, 1637-1649.	1.8	24
645	Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. Journal of Thrombosis and Thrombolysis, 2021, 52, 272-280.	1.0	2

#	Article	IF	Citations
646	The Current Role of Platelet Function Testing in Clinical Practice. Seminars in Thrombosis and Hemostasis, 2021, 47, 843-854.	1.5	6
647	Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial. Journal of Clinical Medicine, 2021, 10, 2699.	1.0	11
648	Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study. Archives of Cardiovascular Diseases, 2021, 114, 612-623.	0.7	0
649	Ticagrelor and prasugrel in acute coronary syndrome: a single-arm crossover platelet reactivity study. Journal of Cardiovascular Medicine, 2021, 22, 686-692.	0.6	3
650	CYP2C19 genotype has prognostic value in specific populations following coronary stenting. Annals of Translational Medicine, 2021, 9, 1066-1066.	0.7	4
651	Platelet Function Testing and Genotyping for Tailoring Treatment in Complex PCI Patients. US Cardiology Review, 0, 15, .	0.5	1
652	Predictors of non-stenting strategy for acute coronary syndrome caused by plaque erosion: four-year outcomes of the EROSION study. EuroIntervention, 2021, 17, 497-505.	1.4	27
653	Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. European Heart Journal, 2021, 42, 4025-4036.	1.0	12
654	The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. Platelets, 2022, 33, 520-530.	1.1	6
655	Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of Cardiovascular Pharmacology, 2021, 78, 463-473.	0.8	1
656	Effect of Adjusted Antiplatelet Therapy on Preventing Ischemic Events After Stenting for Intracranial Aneurysms. Stroke, 2021, 52, 3815-3825.	1.0	24
657	Antithrombotic therapy in high-risk patientsÂafter percutaneous coronary intervention; study design, cohort profile and incidence of adverse events. Netherlands Heart Journal, 2021, 29, 525-535.	0.3	2
658	Impact of morphine dose on ticagrelor uptake and platelet inhibition in patients with ST-segment elevation myocardial infarction â€“ A substudy from the prospective randomized MOVEMENT trial. Thrombosis Update, 2021, 5, 100071.	0.4	1
659	Rotational Thromboelastometry (ROTEMÂ®). , 2016, , 267-298.		28
660	Platelet Function Tests. , 2017, , 559-570.		2
661	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2020, , 711-732.		3
662	Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients. Bioscience Reports, 2020, 40, .	1.1	4
663	Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. Anesthesiology, 2020, 133, 1263-1276.	1.3	12

#	Article	IF	Citations
664	Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Interventionâ€“treated Acute Coronary Syndrome Patients. Journal of Cardiovascular Pharmacology, 2020, 76, 478-488.	0.8	12
665	Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?. Internal Medicine Journal, 2017, 47, 1298-1305.	0.5	16
666	Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. Thrombosis and Haemostasis, 2015, 114, .	1.8	1
667	Discordance Between VASP Phosphorylation and Platelet Aggregation in Defining High On-Clopidogrel Platelet Reactivity After ST-Segment Elevation Myocardial Infarction. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 47-54.	0.7	2
668	High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. PLoS ONE, 2015, 10, e0135037.	1.1	12
669	Coronary Artery-Bypass-Graft Surgery Increases the Plasma Concentration of Exosomes Carrying a Cargo of Cardiac MicroRNAs: An Example of Exosome Trafficking Out of the Human Heart with Potential for Cardiac Biomarker Discovery. PLoS ONE, 2016, 11, e0154274.	1.1	107
670	Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA. Aging, 2020, 12, 20085-20094.	1.4	19
671	Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease. Oncotarget, 2017, 8, 64217-64223.	0.8	6
672	Creatine kinase, energy reserve, and hypertension: from bench to bedside. Annals of Translational Medicine, 2018, 6, 292-292.	0.7	24
673	Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Annals of Translational Medicine, 2019, 7, 408-408.	0.7	10
674	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Ecancermedicalscience, 2020, 14, 998.	0.6	4
675	Variability of Platelet Reactivity on Antiplatelet Therapy in Neurointervention Procedure. Journal of Korean Neurosurgical Society, 2019, 62, 3-9.	0.5	10
676	A pharmacodynamic study of the optimal P2Y₁₂ inhibitor regimen for East Asian patients with acute coronary syndrome. Korean Journal of Internal Medicine, 2015, 30, 620-628.	0.7	21
677	Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor. Korean Circulation Journal, 2019, 49, 1052.	0.7	7
678	Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial. EuroIntervention, 2018, 13, 1931-1938.	1.4	4
679	Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial. EuroIntervention, 2019, 15, e513-e521.	1.4	10
680	Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. EuroIntervention, 2016, 12, 312-318.	1.4	27
681	Organ transplantation and drug eluting stents: Perioperative challenges. World Journal of Transplantation, 2016, 6, 620.	0.6	15

#	Article	IF	Citations
682	Assessment of platelet function: Laboratory and point-of-care methods. World Journal of Translational Medicine, 2014, 3, 69.	3.5	7
683	Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiology Journal, 2020, 27, 780-788.	0.5	8
684	Sex Differences in Platelet Reactivity in Patients With ST-Elevation Myocardial Infarction: A Sub-Analysis of the ON-TIME 3 Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 707814.	1.1	2
685	The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study. Cardiology and Therapy, 2021, 10, 561-568.	1.1	6
686	Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study. Scientific Reports, 2021, 11, 20826.	1.6	4
687	Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China. Frontiers in Cardiovascular Medicine, 2021, 8, 736466.	1.1	6
688	â€œTailoredâ€•antiplatelet bridging therapy with cangrelor: moving toward personalized medicine. Platelets, 2022, 33, 687-691.	1.1	6
689	Testing for Acquired Platelet Disorders. , 2015, , 99-110.		0
690	Shutdown reactivity of platelets to adenosine diphosphate anr arachidoic acid and its prognostic value in patients with myocardial infraction with elevation of ST segment. ScienceRise, 2015, 6, 81.	0.1	0
691	The changes of hemostasis parameters in female patients with miocardium infraction with elevation of ST segment at postmenopause paying attention to the sex hormones levels. ScienceRise, 2015, 12, 88.	0.1	0
692	Inerconnection of the change of vascular-trombocytic hemostasis parameters and sexual hormones level in women with the stable forms of ischemic heart disease in the period of postmenopause. ScienceRise, 2016, 1, 57.	0.1	0
694	Assessment of thrombogenicity in stroke. Japanese Journal of Thrombosis and Hemostasis, 2017, 28, 297-305.	0.1	0
695	Inhibidores del receptor plaquetario P2Y12. Parte 2 de 2: etiologÃa, diagnÃ³stico y manejo de la resistencia. Medicina Y Laboratorio, 2017, 23, 313-348.	0.0	1
696	SALES PROMOTION AND PRICE IMPACT ON PURCHASING DECISION OF XIAOMI SMARTPHONE TO CONSUMERS IN WEST JAKARTA. Russian Journal of Agricultural and Socio-Economic Sciences, 2017, 71, 146-152.	0.1	0
697	Association of serum levels of lipoprotein A-I and lipoprotein A-I/A-II with high on-treatment platelet reactivity in patients with ST-segment elevation myocardial infarction (STEMI).. Anatolian Journal of Cardiology, 2018, 19, 374-381.	0.5	1
698	FEMALE GENDER AS AN ADDITIONAL RISK FACTOR FOR ATHEROTHROMBOTIC COMPLICATIONS OF IHD. World of Medicine and Biology, 2018, 14, 065.	0.1	0
699	Percutaneous Coronary Intervention: Adjunctive Pharmacology. , 2018, , 161-180.		0
700	Effect of Blood Donation on the Donorâ€™s Hemorheological Properties. The Korean Journal of Blood Transfusion, 2018, 29, 229-239.	0.1	0

#	Article	IF	Citations
702	Effectiveness of personalized antiplatelet therapy in patients undergoing coronary stenting: meta-analysis. Complex Issues of Cardiovascular Diseases, 2019, 8, 26-36.	0.3	1
703	Ethnic Differences in Oral Antithrombotic Therapy. Korean Circulation Journal, 2020, 50, 645.	0.7	13
704	PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH BLOOD MALIGNANCY. Vestnik NacionalÊ¹nogo Mediko-hirurgiÄeskogo Centra Im N I Pirogova, 2020, 15, 74-81.	0.0	0
705	Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.4	0
706	ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL. Juvenis Scientia, 2020, 6, 14-24.	0.1	0
708	Antiplatelet Agent Choice and Platelet Function Testing in CKD. , 2020, , 103-118.		0
709	Impact of Pancreatic Î²-Cell Function on Clopidogrel Responsiveness and Outcomes in Chinese Nondiabetic Patients Undergoing Elective Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	2
710	Rotational Thromboelastometry (ROTEMÂ®). , 2021, , 279-312.		3
711	Thromboelastography (TEGÂ® 5000 and TEGÂ® 6s Hemostasis Analyzers with TEG ManagerÂ® Software). , 2021, , 313-331.		2
712	Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients. Journal of Geriatric Cardiology, 2016, 13, 282-9.	0.2	2
713	Platelet Function Testing-Guided Antiplatelet Therapy. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2013, 24, 90-6.	0.7	9
714	Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates. Blood Transfusion, 2016, 14, 545-551.	0.3	4
715	Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate. American Journal of Translational Research (discontinued), 2018, 10, 2175-2183.	0.0	5
716	Shortening Synthetic Routes to Small Molecule Active Pharmaceutical Ingredients Employing Biocatalytic Methods. Chemical Reviews, 2022, 122, 1052-1126.	23.0	105
717	Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy. Frontiers in Cardiovascular Medicine, 2021, 8, 723886.	1.1	42
718	MicroRNAs as Novel Biomarkers for P2Y12 â€“ Inhibitors Resistance Prediction. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1575-1582.	0.4	3
719	Is clopidogrel as the P2Y₁₂ inhibitor a wise choice for long-term monotherapy in patients undergoing stenting?. EuroIntervention, 2021, 17, e865-e866.	1.4	0
720	Platelet Inhibition with Ticagrelor 60Âmg Versus 90Âmg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. Cardiovascular Drugs and Therapy, 2023, 37, 1031-1038.	1.3	3

#	Article	IF	Citations
721	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Cardiovascular Revascularization Medicine, 2022, 41, 115-121.	0.3	4
722	Trimethylamine Nâ€oxide predicts stroke severity in diabetic patients with acute ischaemic stroke and is related to glycemic variability. European Journal of Neurology, 2023, 30, 3478-3486.	1.7	7
723	Platelet Mechanobiology Inspired Microdevices: From Hematological Function Tests to Disease and Drug Screening. Frontiers in Pharmacology, 2021, 12, 779753.	1.6	6
724	Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study. European Heart Journal, 2022, 43, 3556-3574.	1.0	19
725	Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study. Journal of the Formosan Medical Association, 2022, 121, 1786-1797.	0.8	6
726	Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease. Journal of Thrombosis and Haemostasis, 2022, 20, 845-856.	1.9	14
727	Antithrombotic Therapy After AcuteÂCoronary Syndromes or Percutaneous Coronary Interventions inÂEast Asian Populations. JACC Asia, 2022, 2, 1-18.	0.5	15
728	Relationships Among Gut Microbiota, Ischemic Stroke and Its Risk Factors: Based on Research Evidence. International Journal of General Medicine, 0, Volume 15, 2003-2023.	0.8	1
729	Von Willebrand Factor and Platelet Aggregation: from Bench to Clinical Practice. Current Anesthesiology Reports, 0, , 1.	0.9	1
730	P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. European Heart Journal Open, 2022, 2, .	0.9	18
731	Development and Validation of a Novel Tool for the Prediction of Clopidogrel Response in Chinese Acute Coronary Syndrome Patients: The GeneFA Score. Frontiers in Pharmacology, 2022, 13, 854867.	1.6	2
732	Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume. Thrombosis Journal, 2021, 19, 97.	0.9	0
734	Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial. Thrombosis Journal, 2022, 20, 19.	0.9	2
735	Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention. Journal of International Medical Research, 2022, 50, 030006052210817.	0.4	0
736	Performance of the ABCD-GENE Score for Predicting Clinical Outcomes in Clopidogrel-Treated Patients with ACS. Journal of Cardiovascular Translational Research, 2022, 15, 1385-1392.	1.1	2
739	Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease. Journal of Clinical Medicine, 2022, 11, 2380.	1.0	5
740	Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 2480.	1.0	2
742	Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor. Einstein (Sao Paulo, Brazil), 2022, 20, .	0.3	0

#	Article	IF	Citations
743	High onâ€treatment platelet reactivity is associated with poor outcomes after ischemic stroke: A metaâ€analysis. Acta Neurologica Scandinavica, 2022, 146, 205-224.	1.0	1
745	Optimal Duration of Dual Antiplatelet Therapy after Stent- Assisted Coil Embolization of Unruptured Intracranial Aneurysms : A Prospective Randomized Multicenter Trial. Journal of Korean Neurosurgical Society, 2022, 65, 765-771.	0.5	4
746	Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
747	Platelet Reactivity and Outcomes after Off-Pump Coronary Surgery in Acute Coronary Syndrome Patients. Journal of Clinical Medicine, 2022, 11, 3285.	1.0	0
748	Left ventricular-aortic angle is associated with platelet reactivity in patients with aortic stenosis. Blood Coagulation and Fibrinolysis, 0, Publish Ahead of Print, .	0.5	0
749	Postoperative Myocardial Injury and Platelet Reactivity in Patients Undergoing Vascular Surgery. The Platelet Reactivity and Postoperative Myocardial Injury after Major Vascular Surgery (PROMISE) Study. SSRN Electronic Journal, 0, , .	0.4	0
750	Antiplatelet Therapy in End-stage Renal Disease Patients on Maintenance Dialysis: a State-of-the-art Review. Cardiovascular Drugs and Therapy, 2023, 37, 975-987.	1.3	5
751	Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: An open-label crossover study. Frontiers in Pharmacology, 0, 13, .	1.6	0
752	Variability of antiplatelet response in patients with peripheral artery disease. Journal of Vascular Surgery, 2023, 77, 208-215.e3.	0.6	5
753	Clinical pharmacology of antiplatelet drugs. Expert Review of Clinical Pharmacology, 2022, 15, 1177-1197.	1.3	14
754	Postoperative myocardial injury and platelet reactivity in patients undergoing vascular surgery: The platelet reactivity and postoperative myocardial injury after major vascular surgery (PROMISE) study. Thrombosis Research, 2022, 218, 177-185.	0.8	1
755	Effect of cocoa (Theobroma cacao L.) on platelet function testing profiles in patients with coronary artery disease: ECLAIR pilot study. Open Heart, 2022, 9, e002066.	0.9	2
756	Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy. Frontiers in Immunology, 0, 13, .	2.2	0
757	Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor. Minerva Cardiology and Angiology, 0, , .	0.4	0
758	Tongue diagnostic parameters-based diagnostic signature in coronary artery disease patients with clopidogrel resistance after percutaneous coronary intervention. Explore: the Journal of Science and Healing, 2022, , .	0.4	0
759	Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2023, 55, 42-50.	1.0	2
760	Multi-institutional patterns of clopidogrel response among patients undergoing transcarotid artery revascularization. Vascular, 0, , 170853812211422.	0.4	0
761	Predicting Arterial Thrombotic Events Following Peripheral Revascularization Using Objective Viscoelastic Data. Journal of the American Heart Association, 2023, 12, .	1.6	5

#	Article	IF	Citations
762	Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?. Journal of Clinical Medicine, 2022, 11, 7211.	1.0	0
763	Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis. Diabetes Therapy, 0, , .	1.2	0
764	Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study. Thrombosis Journal, 2023, 21, .	0.9	2
765	The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study. International Journal of Clinical Pharmacy, 2023, 45, 461-472.	1.0	1
766	Tailored antiplatelet therapy in stent assisted coiling for unruptured aneurysms: a nationwide registry study. Journal of NeuroInterventional Surgery, 2023, 15, 1095-1104.	2.0	3
767	Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 817-830.	1.5	1
768	Clinical outcomes of individualized antiplatelet therapy based on platelet function test in patients after percutaneous coronary intervention: a systematic review and meta-analysis. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	0.8	1
769	The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic. Medicina (Lithuania), 2023, 59, 84.	0.8	1
770	Role of platelet function testing in acute coronary syndromes: a meta-analysis. Open Heart, 2022, 9, e002129.	0.9	6
771	Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
772	Long-Term Cangrelor Administration in Neurology Intensive Care: A Case Series. A&A Practice, 2023, 17, e01652.	0.2	0
773	Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome. Clinical Pharmacokinetics, 0, , .	1.6	0
774	Ticagrelor Resistance in Cardiovascular Disease and Ischemic Stroke. Journal of Clinical Medicine, 2023, 12, 1149.	1.0	0
775	Monitoring antiplatelet therapy: where are we now?. Journal of Cardiovascular Medicine, 2023, 24, e24-e35.	0.6	4
776	Roles of light transmission aggregometry and CYP2C19 genotype in predicting ischaemic complications during interventional therapy for intracranial aneurysms. Stroke and Vascular Neurology, 2023, 8, 327-334.	1.5	1
777	High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry. Clinical Research in Cardiology, 0, , .	1.5	0
778	Multiple genetic mutations increase the risk of thrombosis associated with clopidogrel after percutaneous coronary intervention. Pharmacogenomics, 2023, 24, 227-237.	0.6	0
779	Aspirin should be stopped at day 0 after PCI: pros and cons. EuroIntervention, 2023, 18, e1304-e1306.	1.4	0

#	Article	IF	Citations
780	Current concepts and novel targets for antiplatelet therapy. Nature Reviews Cardiology, 2023, 20, 583-599.	6.1	7
781	Identification of high platelet reactivity despite P2Y12 inhibitor treatment: Two populations in the VASP assay and variable PFA-P2Y shapes of curve. TH Open, 0, , .	0.7	0
782	Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease. Platelets, 2023, 34, .	1.1	0
790	Modification of the Bacterial Metabolites by the Host after Absorption, and Consequences for the Peripheral Tissuesâ€™ Metabolism, Physiology, and Physiopathology. , 2023, , 189-246.		0
794	Extracellular Vesicles in Coronary Artery Disease. Advances in Experimental Medicine and Biology, 2023, , 81-103.	0.8	2